Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRO-15: Olvi-Vec in Recurrent or Refractory Ovarian Cancer
NCT02759588Phase 2Completed
- Sponsor
- Genelux Corporation
- Start
- May 2016
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of olvimulogene nanivacirepvec in ovarian cancer, peritoneal carcinomatosis (PC) and fallopian tube cancer (PFTC) (4 arms), sponsored by Genelux Corporation. Primary endpoints: Treatment-emergent Adverse Events, Progression-free Survival up to 24 months and 2 more. Started May 2016; status: completed.
02
Drugs
olvimulogene nanivacirepvec
03
Conditions
ovarian cancerperitoneal carcinomatosis (PC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT02759588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759588.